![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Objective:
To compare the risk of developing uveitis in patients initiating anti-tumor necrosis factor (anti-TNF) agents (adalimumab, etanercept, and infliximab) for ankylosing spondylitis (AS).
Methods:
Anti-TNF-naive patients with a diagnosis of AS and without a history of uveitis (N = 2115) who subsequently initiated anti-TNF therapy for AS were identified in a large claims database (2005 to 2011). A multivariate Cox proportional-hazards model was used to compare the risk of uveitis in patients who received etanercept or infliximab vs adalimumab.
Results:
The median number of days to the first occurrence of uveitis after initiation of anti-TNF was 191. Among the three anti-TNF groups, the median time to event of uveitis was longest in patients taking adalimumab (243 days), followed by etanercept (182 days) and infliximab (144 days). The incidence rate for uveitis over 1 year was lowest for patients who received adalimumab (2.4%, N = 717), highest for patients who received etanercept (4.5%, N = 1087), and intermediate for patients who received infliximab (3.2%, N = 311). The risk of uveitis was 1.9 times higher in patients receiving etanercept compared with those taking adalimumab (hazard ratio [HR]: 1.91, 95% confidence interval [CI]: 1.1 to 3.31). For patients taking infliximab, the risk of uveitis was not statistically significantly different (HR: 1.35, 95% CI: 0.62 to 2.95) compared to adalimumab.
Conclusion:
The results indicated that initial adalimumab therapy is associated with a significantly lower risk of developing uveitis compared to initial etanercept therapy in patients diagnosed with AS and no prior history of uveitis; however, the risk was not different between adalimumab and infliximab. Limitations to consider when interpreting this conclusion include that disease-level clinical data, such as disease duration, were not available for inclusion in the model and that risk of uveitis beyond 1 year was not evaluated.
Transparency
Declaration of funding
This study was funded in full by AbbVie Inc., North Chicago, IL, United States.
AbbVie Inc. participated in the study design, research, data collection, analysis and interpretation, writing, review, and approval of this publication. All authors had access to the data and participated in the development, review, approval, and decision to submit this publication.
Declaration of financial/other relationships
D.W. has disclosed that he has participated in advisory boards for AbbVie, MSD, Pfizer, Roche Chugai, and Sobi; received speaking fees from AbbVie, MSD, Pfizer, Roche Chugai, Amgen, UCB, Nordic, and BMS; and received grants from AbbVie, Pfizer, and Roche Chugai. A.J. has disclosed that he is a shareholder in AbbVie and an employee of AbbVie. P.R. has disclosed that he is a contractor with AbbVie. Y.J.J. has disclosed that he is from the University of Illinois at Chicago and is a summer intern at AbbVie. M.M. has disclosed that he is a shareholder in AbbVie and an employee of AbbVie. Y.B. has disclosed that she is a shareholder in AbbVie and an employee of AbbVie.
CMRO peer reviewers on this manuscript have received an honorarium from CMRO for their review work, but have no relevant financial or other relationships to disclose.
Acknowledgments
Medical writing services were provided by Cathryn M. Carter MS and Tracey Fine MS ELS of Arbor Communications Inc., Ann Arbor, Michigan, United States; this support was funded by AbbVie.
Previous presentation: Data from the manuscript have been previously presented at the European League Against Rheumatism Congress, 25–28 May 2011, London, United Kingdom.